Pazdur resignation adds to FDA process uncertainty - bearish for sector sentiment, but the edge is decaying
The Opportunity
The bearish mechanism is regulatory-process uncertainty: leadership conflict and process changes around trial requirements tend to widen risk premia across pharma, even if individual outcomes differ by company. 7A keeps the direction SHORT because this kind of governance and standards noise is generally negative for sentiment and can slow risk-taking in development-stage names. The caveat is structural: this is already spreading, so the edge is not in discovery but in framing the read-through correctly.
The Timing
Mixed 55 with crosswind 60 is consistent with choppy policy sensitivity rather than a one-way tape. Trade confidence is 39 while conviction is 44, reflecting that execution is not clean. The conversion triggers are additional primary FDA/HHS artefacts or Tier-1 amplification that shifts the story from personnel drama to concrete procedural change; absent that, it remains a sector sentiment overhang rather than a discrete earnings event.
The Evidence
Hydrated evidence is the BioSpace report at biospace.com . Upstream summary explicitly references a December policy change claim (one trial vs two) and leadership replacement details, and 7A labels the lifecycle as spreading with decaying edge because Tier-1 coverage is already present in the broader cluster.